<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.18.0.post9+e462414&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240517141110&amp;utm_source=Chrome&amp;utm_campaign=pubmed-2
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.18.0.post9+e462414&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240517141110&amp;utm_source=Chrome&amp;utm_campaign=pubmed-2" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Fri, 17 May 2024 18:11:10 +0000</lastbuilddate>
<pubDate>Fri, 17 May 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Obesity paradox can be a fact: unveiling the hidden role of adipose tissue</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38757797/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240517141110&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 May 17:ehae239. doi: 10.1093/eurheartj/ehae239. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38757797/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240517141110&v=2.18.0.post9+e462414">38757797</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae239>10.1093/eurheartj/ehae239</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38757797</guid>
<pubDate>Fri, 17 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Jawad H Butt</dc:creator>
<dc:creator>John J V McMurray</dc:creator>
<dc:date>2024-05-17</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Obesity paradox can be a fact: unveiling the hidden role of adipose tissue</dc:title>
<dc:identifier>pmid:38757797</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae239</dc:identifier>
</item>
<item>
<title>Incident heart failure in chronic kidney disease: proteomics informs biology and risk stratification</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38757788/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240517141110&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Large-scale proteomics reveal novel circulating protein biomarkers and potential mediators of HF in CKD. Proteomic risk models improve upon the PCP-HF risk score in this population.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 May 17:ehae288. doi: 10.1093/eurheartj/ehae288. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Incident heart failure (HF) among individuals with chronic kidney disease (CKD) incurs hospitalizations that burden patients and health care systems. There are few preventative therapies, and the Pooled Cohort equations to Prevent Heart Failure (PCP-HF) perform poorly in the setting of CKD. New drug targets and better risk stratification are urgently needed.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: In this analysis of incident HF, SomaScan V4.0 (4638 proteins) was analysed in 2906 participants of the Chronic Renal Insufficiency Cohort (CRIC) with validation in the Atherosclerosis Risk in Communities (ARIC) study. The primary outcome was 14-year incident HF (390 events); secondary outcomes included 4-year HF (183 events), HF with reduced ejection fraction (137 events), and HF with preserved ejection fraction (165 events). Mendelian randomization and Gene Ontology were applied to examine causality and pathways. The performance of novel multi-protein risk models was compared to the PCP-HF risk score.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Over 200 proteins were associated with incident HF after adjustment for estimated glomerular filtration rate at P &lt; 1 × 10-5. After adjustment for covariates including N-terminal pro-B-type natriuretic peptide, 17 proteins remained associated at P &lt; 1 × 10-5. Mendelian randomization associations were found for six proteins, of which four are druggable targets: FCG2B, IGFBP3, CAH6, and ASGR1. For the primary outcome, the C-statistic (95% confidence interval [CI]) for the 48-protein model in CRIC was 0.790 (0.735, 0.844) vs. 0.703 (0.644, 0.762) for the PCP-HF model (P = .001). C-statistic (95% CI) for the protein model in ARIC was 0.747 (0.707, 0.787).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Large-scale proteomics reveal novel circulating protein biomarkers and potential mediators of HF in CKD. Proteomic risk models improve upon the PCP-HF risk score in this population.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38757788/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240517141110&v=2.18.0.post9+e462414">38757788</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae288>10.1093/eurheartj/ehae288</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38757788</guid>
<pubDate>Fri, 17 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Ruth F Dubin</dc:creator>
<dc:creator>Rajat Deo</dc:creator>
<dc:creator>Yue Ren</dc:creator>
<dc:creator>Jianqiao Wang</dc:creator>
<dc:creator>Alexander R Pico</dc:creator>
<dc:creator>Josyf C Mychaleckyj</dc:creator>
<dc:creator>Julia Kozlitina</dc:creator>
<dc:creator>Victoria Arthur</dc:creator>
<dc:creator>Hongzhe Lee</dc:creator>
<dc:creator>Amil Shah</dc:creator>
<dc:creator>Harold Feldman</dc:creator>
<dc:creator>Nisha Bansal</dc:creator>
<dc:creator>Leila Zelnick</dc:creator>
<dc:creator>Panduranga Rao</dc:creator>
<dc:creator>Nidhi Sukul</dc:creator>
<dc:creator>Dominic S Raj</dc:creator>
<dc:creator>Rupal Mehta</dc:creator>
<dc:creator>Sylvia E Rosas</dc:creator>
<dc:creator>Zeenat Bhat</dc:creator>
<dc:creator>Matthew R Weir</dc:creator>
<dc:creator>Jiang He</dc:creator>
<dc:creator>Jing Chen</dc:creator>
<dc:creator>Mayank Kansal</dc:creator>
<dc:creator>Paul L Kimmel</dc:creator>
<dc:creator>Vasan S Ramachandran</dc:creator>
<dc:creator>Sushrut S Waikar</dc:creator>
<dc:creator>Mark R Segal</dc:creator>
<dc:creator>Peter Ganz</dc:creator>
<dc:creator>CRIC Study Investigators</dc:creator>
<dc:date>2024-05-17</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Incident heart failure in chronic kidney disease: proteomics informs biology and risk stratification</dc:title>
<dc:identifier>pmid:38757788</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae288</dc:identifier>
</item>
<item>
<title>Obesity paradox can be a fact: unveiling the hidden role of adipose tissue</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38757778/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240517141110&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 May 17:ehae236. doi: 10.1093/eurheartj/ehae236. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38757778/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240517141110&v=2.18.0.post9+e462414">38757778</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae236>10.1093/eurheartj/ehae236</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38757778</guid>
<pubDate>Fri, 17 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Duk-Hee Lee</dc:creator>
<dc:date>2024-05-17</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Obesity paradox can be a fact: unveiling the hidden role of adipose tissue</dc:title>
<dc:identifier>pmid:38757778</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae236</dc:identifier>
</item>
<item>
<title>Managing Iatrogenic Aortic Dissection: Insight from 3D-holographic Imaging and CT Computational Fluid Dynamic Simulations</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38754705/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240517141110&amp;v=2.18.0.post9+e462414
      <description>Iatrogenic aortic dissection is a rare but life-threatening complication of coronary artery bypass surgery. We report a case with incidentally detected iatrogenic aortic dissection related to aorta cross-clamping successfully managed with watchful follow-up. The decision-making was based on 3D hologram and fluid dynamic analysis guidance.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 May 1:S0735-1097(24)07129-8. doi: 10.1016/j.jacc.2024.04.040. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Iatrogenic aortic dissection is a rare but life-threatening complication of coronary artery bypass surgery. We report a case with incidentally detected iatrogenic aortic dissection related to aorta cross-clamping successfully managed with watchful follow-up. The decision-making was based on 3D hologram and fluid dynamic analysis guidance.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38754705/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240517141110&v=2.18.0.post9+e462414">38754705</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.04.040>10.1016/j.jacc.2024.04.040</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38754705</guid>
<pubDate>Thu, 16 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Tsung-Ying Tsai</dc:creator>
<dc:creator>Xiao-Jing Guo</dc:creator>
<dc:creator>Shigetaka Kageyama</dc:creator>
<dc:creator>Ruth P Lim</dc:creator>
<dc:creator>Kaoru Tanaka</dc:creator>
<dc:creator>Johan De Mey</dc:creator>
<dc:creator>Mark La Meir</dc:creator>
<dc:creator>Yoshinobu Onuma</dc:creator>
<dc:creator>Eric K W Poon</dc:creator>
<dc:creator>Patrick W Serruys</dc:creator>
<dc:date>2024-05-16</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Managing Iatrogenic Aortic Dissection: Insight from 3D-holographic Imaging and CT Computational Fluid Dynamic Simulations</dc:title>
<dc:identifier>pmid:38754705</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.04.040</dc:identifier>
</item>
<item>
<title>The Influence Of Epicardial Resistance On Microvascular Resistance Reserve</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38754704/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240517141110&amp;v=2.18.0.post9+e462414
      <description>CONCLUSION: MRR, unlike CFR, is minimally influenced by epicardial resistance, and thus should be considered the more specific index of microvascular function. This suggests that MRR can also reliably evaluate microvascular function in patients with significant epicardial disease.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 May 9:S0735-1097(24)07198-5. doi: 10.1016/j.jacc.2024.05.004. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The optimal index of microvascular function should be specific for the microvascular compartment. Yet, coronary flow reserve (CFR), despite being widely used to diagnose coronary microvascular dysfunction (CMD), is influenced by both epicardial and microvascular resistance. Conversely, microvascular resistance reserve (MRR) adjusts for fractional flow reserve (FFR), and thus is theoretically independent of epicardial resistance.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: We tested the hypothesis that MRR, unlike CFR, is not influenced by increasing epicardial resistance, and thus is a more specific index of microvascular function.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: In a cohort of 16 patients that had undergone proximal left anterior descending artery stenting, we created four grades of artificial stenosis (no stenosis, mild, moderate, and severe) using a coronary angioplasty balloon inflated to different degrees within the stent. For each stenosis grade, we calculated CFR and MRR using continuous thermodilution (64 measurements of each) in order to assess their response to changing epicardial resistance.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Graded balloon inflation resulted in a significant sequential decrease in mean FFR (no stenosis: 0.82 ±0.05; mild: 0.72 ±0.04; moderate: 0.61 ±0.05; severe: 0.48 ±0.09, p&lt;0.001). This translated into a linear decrease in mean hyperaemic coronary flow (no stenosis: 170.5 ±66.8 ml/min; mild: 149.8 ±58.8 ml/min; moderate: 124.4 ±53.0 ml/min; severe: 94.0 ±45.2 ml/min, p&lt;0.001). CFR exhibited a marked linear decrease with increasing stenosis (no stenosis: 2.5 ±0.9; mild: 2.2 ±0.8; moderate: 1.8 ±0.7; severe: 1.4 ±0.6), corresponding to a decrease of 0.3 for a decrease in FFR of 0.1 (p&lt;0.001). In contrast, MRR exhibited a negligible decrease across all stenosis grades (no stenosis: 3.0 ±1.0; mild: 3.0 ±1.0; moderate: 2.9 ±1.0; severe: 2.8 ±1.0), corresponding to a decrease of just 0.05 for a decrease in FFR of 0.1 (p&lt;0.001).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSION: MRR, unlike CFR, is minimally influenced by epicardial resistance, and thus should be considered the more specific index of microvascular function. This suggests that MRR can also reliably evaluate microvascular function in patients with significant epicardial disease.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38754704/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240517141110&v=2.18.0.post9+e462414">38754704</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.05.004>10.1016/j.jacc.2024.05.004</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38754704</guid>
<pubDate>Thu, 16 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Thabo Mahendiran</dc:creator>
<dc:creator>Dario Bertolone</dc:creator>
<dc:creator>Michele Viscusi</dc:creator>
<dc:creator>Emanuele Gallinoro</dc:creator>
<dc:creator>Danielle Keulards</dc:creator>
<dc:creator>Carlos Collet</dc:creator>
<dc:creator>Jeroen Sonck</dc:creator>
<dc:creator>Adriaan Wilgenhof</dc:creator>
<dc:creator>Nico Hj Pijls</dc:creator>
<dc:creator>Bernard De Bruyne</dc:creator>
<dc:date>2024-05-16</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>The Influence Of Epicardial Resistance On Microvascular Resistance Reserve</dc:title>
<dc:identifier>pmid:38754704</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.05.004</dc:identifier>
</item>
<item>
<title>A vision for global eDNA-based monitoring in a changing world</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38754422/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240517141110&amp;v=2.18.0.post9+e462414
      <description>Environmental DNA (eDNA) has opened promising avenues for establishing standardized, cost-efficient monitoring of biodiversity. However, comprehensive and systematic implementation is urgently needed to address the current biodiversity crisis. Here, we envision a global eDNA biomonitoring scheme, which could potentially revolutionize the understanding and conservation of life on Earth.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 May 9:S0092-8674(24)00444-6. doi: 10.1016/j.cell.2024.04.019. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Environmental DNA (eDNA) has opened promising avenues for establishing standardized, cost-efficient monitoring of biodiversity. However, comprehensive and systematic implementation is urgently needed to address the current biodiversity crisis. Here, we envision a global eDNA biomonitoring scheme, which could potentially revolutionize the understanding and conservation of life on Earth.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38754422/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240517141110&v=2.18.0.post9+e462414">38754422</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.04.019>10.1016/j.cell.2024.04.019</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38754422</guid>
<pubDate>Thu, 16 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Philip Francis Thomsen</dc:creator>
<dc:creator>Mads Reinholdt Jensen</dc:creator>
<dc:creator>Eva Egelyng Sigsgaard</dc:creator>
<dc:date>2024-05-16</dc:date>
<dc:source>Cell</dc:source>
<dc:title>A vision for global eDNA-based monitoring in a changing world</dc:title>
<dc:identifier>pmid:38754422</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.04.019</dc:identifier>
</item>
<item>
<title>ARID1A suppresses R-loop-mediated STING-type I interferon pathway activation of anti-tumor immunity</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38754421/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240517141110&amp;v=2.18.0.post9+e462414
      <description>Clinical trials have identified ARID1A mutations as enriched among patients who respond favorably to immune checkpoint blockade (ICB) in several solid tumor types independent of microsatellite instability. We show that ARID1A loss in murine models is sufficient to induce anti-tumor immune phenotypes observed in ARID1A mutant human cancers, including increased CD8+ T cell infiltration and cytolytic activity. ARID1A-deficient cancers upregulated an interferon (IFN) gene expression signature, the...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 May 9:S0092-8674(24)00451-3. doi: 10.1016/j.cell.2024.04.025. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Clinical trials have identified ARID1A mutations as enriched among patients who respond favorably to immune checkpoint blockade (ICB) in several solid tumor types independent of microsatellite instability. We show that ARID1A loss in murine models is sufficient to induce anti-tumor immune phenotypes observed in ARID1A mutant human cancers, including increased CD8+ T cell infiltration and cytolytic activity. ARID1A-deficient cancers upregulated an interferon (IFN) gene expression signature, the ARID1A-IFN signature, associated with increased R-loops and cytosolic single-stranded DNA (ssDNA). Overexpression of the R-loop resolving enzyme, RNASEH2B, or cytosolic DNase, TREX1, in ARID1A-deficient cells prevented cytosolic ssDNA accumulation and ARID1A-IFN gene upregulation. Further, the ARID1A-IFN signature and anti-tumor immunity were driven by STING-dependent type I IFN signaling, which was required for improved responsiveness of ARID1A mutant tumors to ICB treatment. These findings define a molecular mechanism underlying anti-tumor immunity in ARID1A mutant cancers.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38754421/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240517141110&v=2.18.0.post9+e462414">38754421</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.04.025>10.1016/j.cell.2024.04.025</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38754421</guid>
<pubDate>Thu, 16 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Matthew B Maxwell</dc:creator>
<dc:creator>Marianne S Hom-Tedla</dc:creator>
<dc:creator>Jawoon Yi</dc:creator>
<dc:creator>Shitian Li</dc:creator>
<dc:creator>Samuel A Rivera</dc:creator>
<dc:creator>Jingting Yu</dc:creator>
<dc:creator>Mannix J Burns</dc:creator>
<dc:creator>Helen M McRae</dc:creator>
<dc:creator>Braden T Stevenson</dc:creator>
<dc:creator>Katherine E Coakley</dc:creator>
<dc:creator>Josephine Ho</dc:creator>
<dc:creator>Kameneff Bojorquez Gastelum</dc:creator>
<dc:creator>Joshua C Bell</dc:creator>
<dc:creator>Alexander C Jones</dc:creator>
<dc:creator>Ramez N Eskander</dc:creator>
<dc:creator>Emily C Dykhuizen</dc:creator>
<dc:creator>Gerald S Shadel</dc:creator>
<dc:creator>Susan M Kaech</dc:creator>
<dc:creator>Diana C Hargreaves</dc:creator>
<dc:date>2024-05-16</dc:date>
<dc:source>Cell</dc:source>
<dc:title>ARID1A suppresses R-loop-mediated STING-type I interferon pathway activation of anti-tumor immunity</dc:title>
<dc:identifier>pmid:38754421</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.04.025</dc:identifier>
</item>
<item>
<title>Cortico-limbic interactions and carotid atherosclerotic burden during chronic stress exposure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38753456/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240517141110&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In this study of limited size, participants with PTSD did not have higher atherosclerotic inflammation than controls. Notably, impaired cortico-limbic interactions (higher amygdala relative to vmPFC activity or disruption of their intercommunication) associated with carotid atherosclerotic burden. Larger studies are needed to refine these findings.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 May 16:ehae149. doi: 10.1093/eurheartj/ehae149. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Chronic stress associates with cardiovascular disease, but mechanisms remain incompletely defined. Advanced imaging was used to identify stress-related neural imaging phenotypes associated with atherosclerosis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Twenty-seven individuals with post-traumatic stress disorder (PTSD), 45 trauma-exposed controls without PTSD, and 22 healthy controls underwent 18F-fluorodeoxyglucose positron emission tomography/magnetic resonance imaging (18F-FDG PET/MRI). Atherosclerotic inflammation and burden were assessed using 18F-FDG PET (as maximal target-to-background ratio, TBR max) and MRI, respectively. Inflammation was assessed using high-sensitivity C-reactive protein (hsCRP) and leucopoietic imaging (18F-FDG PET uptake in spleen and bone marrow). Stress-associated neural network activity (SNA) was assessed on 18F-FDG PET as amygdala relative to ventromedial prefrontal cortex (vmPFC) activity. MRI diffusion tensor imaging assessed the axonal integrity (AI) of the uncinate fasciculus (major white matter tract connecting vmPFC and amygdala).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Median age was 37 years old and 54% of participants were female. There were no significant differences in atherosclerotic inflammation between participants with PTSD and controls; adjusted mean difference in TBR max (95% confidence interval) of the aorta 0.020 (-0.098, 0.138), and of the carotids 0.014 (-0.091, 0.119). Participants with PTSD had higher hsCRP, spleen activity, and aorta atherosclerotic burden (normalized wall index). Participants with PTSD also had higher SNA and lower AI. Across the cohort, carotid atherosclerotic burden (standard deviation of wall thickness) associated positively with SNA and negatively with AI independent of Framingham risk score.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In this study of limited size, participants with PTSD did not have higher atherosclerotic inflammation than controls. Notably, impaired cortico-limbic interactions (higher amygdala relative to vmPFC activity or disruption of their intercommunication) associated with carotid atherosclerotic burden. Larger studies are needed to refine these findings.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38753456/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240517141110&v=2.18.0.post9+e462414">38753456</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae149>10.1093/eurheartj/ehae149</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38753456</guid>
<pubDate>Thu, 16 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Charbel Gharios</dc:creator>
<dc:creator>Mandy M T van Leent</dc:creator>
<dc:creator>Helena L Chang</dc:creator>
<dc:creator>Shady Abohashem</dc:creator>
<dc:creator>David O'Connor</dc:creator>
<dc:creator>Michael T Osborne</dc:creator>
<dc:creator>Cheuk Y Tang</dc:creator>
<dc:creator>Audrey E Kaufman</dc:creator>
<dc:creator>Philip M Robson</dc:creator>
<dc:creator>Sarayu Ramachandran</dc:creator>
<dc:creator>Claudia Calcagno</dc:creator>
<dc:creator>Venkatesh Mani</dc:creator>
<dc:creator>Maria Giovanna Trivieri</dc:creator>
<dc:creator>Antonia V Seligowski</dc:creator>
<dc:creator>Sharon Dekel</dc:creator>
<dc:creator>Willem J M Mulder</dc:creator>
<dc:creator>James W Murrough</dc:creator>
<dc:creator>Lisa M Shin</dc:creator>
<dc:creator>Ahmed Tawakol</dc:creator>
<dc:creator>Zahi A Fayad</dc:creator>
<dc:date>2024-05-16</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Cortico-limbic interactions and carotid atherosclerotic burden during chronic stress exposure</dc:title>
<dc:identifier>pmid:38753456</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae149</dc:identifier>
</item>
<item>
<title>Early Versus Late Initiation of Direct Oral Anticoagulants After Ischemic Stroke in People With Atrial Fibrillation and Hemorrhagic Transformation: Prespecified Subanalysis of the Randomized-controlled ELAN Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38753452/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240517141110&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: We found no evidence of major treatment effect heterogeneity or safety concerns with early versus late DOAC initiation in people with and without HT. However, early DOAC initiation may worsen functional outcomes in people with PH.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 May 16. doi: 10.1161/CIRCULATIONAHA.124.069324. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Whether hemorrhagic transformation (HT) modifies the treatment effect of early versus late initiation of direct oral anticoagulation (DOAC) in people with ischemic stroke and atrial fibrillation is unknown.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This is a post-hoc analysis of the ELAN trial. The primary outcome was a composite of recurrent ischemic stroke, symptomatic intracranial hemorrhage (sICH), major extracranial bleeding, systemic embolism, or vascular death within 30 days. Secondary outcomes were the individual components, 30- and 90-day functional outcome. We estimated outcomes based on HT, subclassified as hemorrhagic infarction (HI) or parenchymal hemorrhage (PH) on pre-randomization imaging (core-lab rating) using adjusted risk differences (aRD) between treatment arms.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Overall, 247/1970 (12.5%) participants had HT (114 HI 1, 77 HI 2, 34 PH 1, 22 PH 2). For the primary outcome, the estimated aRD (early versus late) was -2.2% (-7.8 to 3.5%) in people with HT (HI: -4.7%, -10.8 to 1.4%; PH: 6.1%, -8.4 to 20.7%), and -0.9% (-2.6 to 0.8%) in people without. Numbers of sICH were identical in people with and without HT. With early treatment, the estimated aRD for poor 90-day functional outcome (mRS 3-6) was 11.4% (-0.9 to 23.7%) in participants with HT (HI: 7.2%, -6.6 to 21.0%; PH: 25.1%, 0.2 to 50.0%), and -2.6% (-7.1 to 1.8%) in people without HT.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: We found no evidence of major treatment effect heterogeneity or safety concerns with early versus late DOAC initiation in people with and without HT. However, early DOAC initiation may worsen functional outcomes in people with PH.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38753452/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240517141110&v=2.18.0.post9+e462414">38753452</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069324>10.1161/CIRCULATIONAHA.124.069324</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38753452</guid>
<pubDate>Thu, 16 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Roman Rohner</dc:creator>
<dc:creator>Markus Kneihsl</dc:creator>
<dc:creator>Martina B Goeldlin</dc:creator>
<dc:creator>Arsany Hakim</dc:creator>
<dc:creator>Mattia Branca</dc:creator>
<dc:creator>Stefanie Abend</dc:creator>
<dc:creator>Waldo Valenzuela Pinilla</dc:creator>
<dc:creator>Sabine Fenzl</dc:creator>
<dc:creator>Beata Rezny-Kasprzak</dc:creator>
<dc:creator>Daniel Strbian</dc:creator>
<dc:creator>Sven Trelle</dc:creator>
<dc:creator>Maurizio Paciaroni</dc:creator>
<dc:creator>Götz Thomalla</dc:creator>
<dc:creator>Patrik Michel</dc:creator>
<dc:creator>Krassen Nedeltchev</dc:creator>
<dc:creator>Thomas Gattringer</dc:creator>
<dc:creator>Else C Sandset</dc:creator>
<dc:creator>Leo Bonati</dc:creator>
<dc:creator>Diana Aguiar de Sousa</dc:creator>
<dc:creator>P N Sylaja</dc:creator>
<dc:creator>George Ntaios</dc:creator>
<dc:creator>Masatoshi Koga</dc:creator>
<dc:creator>Zuzana Gdovinova</dc:creator>
<dc:creator>Robin Lemmens</dc:creator>
<dc:creator>Natan M Bornstein</dc:creator>
<dc:creator>Peter Kelly</dc:creator>
<dc:creator>Mira Katan</dc:creator>
<dc:creator>Thomas Horvath</dc:creator>
<dc:creator>Jesse Dawson</dc:creator>
<dc:creator>Urs Fischer</dc:creator>
<dc:creator>ELAN Investigators</dc:creator>
<dc:date>2024-05-16</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Early Versus Late Initiation of Direct Oral Anticoagulants After Ischemic Stroke in People With Atrial Fibrillation and Hemorrhagic Transformation: Prespecified Subanalysis of the Randomized-controlled ELAN Trial</dc:title>
<dc:identifier>pmid:38753452</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069324</dc:identifier>
</item>
<item>
<title>N-of-1 Trial of Angina Verification Before Percutaneous Coronary Intervention</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38752902/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240517141110&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Similarity score powerfully predicted symptom improvement from PCI. These data lay the foundation for independent symptom mapping to target PCI to those patients most likely to benefit. (Systematic Trial of Angina Assessment Before Revascularization [ORBITA-STAR]; NCT04280575).</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 May 8:S0735-1097(24)06824-4. doi: 10.1016/j.jacc.2024.04.001. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: In stable coronary artery disease, 30% to 60% of patients remain symptomatic despite successful revascularization. Perhaps not all symptoms reported by a patient with myocardial ischemia are, in fact, angina.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This study sought to determine whether independent symptom verification using a placebo-controlled ischemic stimulus could distinguish which patients achieve greatest symptom relief from percutaneous coronary intervention (PCI).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: ORBITA-STAR was a multicenter, n-of-1, placebo-controlled study in patients undergoing single-vessel PCI for stable symptoms. Participants underwent 4 episodes (60 seconds each) of low-pressure balloon occlusion across their coronary stenosis, randomly paired with 4 episodes of placebo inflation. Following each episode, patients reported the similarity of the induced symptom in comparison with their usual symptom. The similarity score ranged from -10 (placebo replicated the symptom more than balloon occlusion) to +10 (balloon occlusion exactly replicated the symptom). The primary endpoint was the ability of the similarity score to predict symptom relief with PCI.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Fifty-one patients were recruited, aged 62.9 ± 8.6 years. The median fractional flow reserve was 0.68 (Q1-Q3: 0.57-0.79), and the instantaneous wave-free ratio was 0.80 (Q1-Q3: 0.48-0.89). The median similarity score was 3 (Q1-Q3: 0.875-5.25). The similarity score was a strong predictor of symptom improvement following PCI: a patient with an upper quartile similarity score of 5.25 was significantly more likely to have lower angina frequency at follow-up (OR: 8.01; 95% credible interval: 2.39-15.86) than a patient with a lower quartile similarity score of 0.875 (OR: 1.31; 95% credible interval: 0.71-1.99), Pr<sub>(difference)</sub> >;99.9%.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Similarity score powerfully predicted symptom improvement from PCI. These data lay the foundation for independent symptom mapping to target PCI to those patients most likely to benefit. (Systematic Trial of Angina Assessment Before Revascularization [ORBITA-STAR]; NCT04280575).</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38752902/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240517141110&v=2.18.0.post9+e462414">38752902</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.04.001>10.1016/j.jacc.2024.04.001</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38752902</guid>
<pubDate>Thu, 16 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Christopher A Rajkumar</dc:creator>
<dc:creator>Michael J Foley</dc:creator>
<dc:creator>Fiyyaz Ahmed-Jushuf</dc:creator>
<dc:creator>Florentina A Simader</dc:creator>
<dc:creator>Muhammad Mohsin</dc:creator>
<dc:creator>Sashiananthan Ganesananthan</dc:creator>
<dc:creator>Alexandra N Nowbar</dc:creator>
<dc:creator>Shayna Chotai</dc:creator>
<dc:creator>Sayan Sen</dc:creator>
<dc:creator>Ricardo Petraco</dc:creator>
<dc:creator>Sukhjinder S Nijjer</dc:creator>
<dc:creator>Joban Sehmi</dc:creator>
<dc:creator>Neil Ruparelia</dc:creator>
<dc:creator>Jason N Dungu</dc:creator>
<dc:creator>Alamgir Kabir</dc:creator>
<dc:creator>Kare Tang</dc:creator>
<dc:creator>Reto Gamma</dc:creator>
<dc:creator>John R Davies</dc:creator>
<dc:creator>Tushar Kotecha</dc:creator>
<dc:creator>Graham D Cole</dc:creator>
<dc:creator>James P Howard</dc:creator>
<dc:creator>Thomas R Keeble</dc:creator>
<dc:creator>Gerald Clesham</dc:creator>
<dc:creator>Peter D O'Kane</dc:creator>
<dc:creator>Frank E Harrell</dc:creator>
<dc:creator>Darrel P Francis</dc:creator>
<dc:creator>Matthew J Shun-Shin</dc:creator>
<dc:creator>Rasha K Al-Lamee</dc:creator>
<dc:date>2024-05-16</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>N-of-1 Trial of Angina Verification Before Percutaneous Coronary Intervention</dc:title>
<dc:identifier>pmid:38752902</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.04.001</dc:identifier>
</item>
<item>
<title>Glycemic Control and Coronary Stent Failure in Patients With Type 2 Diabetes Mellitus</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38752901/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240517141110&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: We found a significant association between poor glycemic control and a higher risk of stent failure driven by in-stent restenosis.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 May 7:S0735-1097(24)06933-X. doi: 10.1016/j.jacc.2024.04.012. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The impact of glycemic control in the risk of stent failure in subjects with type 2 diabetes (T2D) is currently unknown.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This study sought to study whether poor glycemic control is associated with a higher risk of stent failure in subjects with T2D.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This observational study included all patients in Sweden with T2D who underwent implantation of second-generation drug-eluting stents (DES) during 2010 to 2020. The exposure variable was the updated mean of glycated hemoglobin (HbA<sub>1c</sub>). Individuals were stratified by glycemic control, with HbA<sub>1c</sub> 6.1% to 7.0% (43-53 mmol/mol) as the reference group. The primary endpoint was the occurrence of stent failure (in-stent restenosis and stent thrombosis). The main result was analyzed in a complete cases model. Sensitivity analyses were performed for missing data and a model with death as a competing risk.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The study population consisted of 52,457 individuals (70,453 DES). The number of complete cases was 24,411 (29,029 DES). The median follow-up was 6.4 years. The fully adjusted HR was 1.10 (95% CI: 0.80-1.52) for HbA<sub>1c</sub> of ≤5.5% (≤37 mmol/mol), 1.02 (95% CI: 0.85-1.23) for HbA<sub>1c</sub> of 5.6% to 6.0% (38-42 mmol/mol), 1.25 (95% CI: 1.11-1.41) for HbA<sub>1c</sub> of 7.1% to 8.0% (54-64 mmol/mol), 1.30 (95% CI: 1.13-1.51) for HbA<sub>1c</sub> of 8.1% to 9.0% (65-75 mmol/mol), 1.46 (95% CI: 1.21-1.76) for HbA<sub>1c</sub> of 9.1% to 10.0% (76-86 mmol/mol), and 1.33 (95% CI: 1.06-1.66) for HbA<sub>1c</sub> of ≥10.1% (≥87 mmol/mol). Sensitivity analyses did not change the main result.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: We found a significant association between poor glycemic control and a higher risk of stent failure driven by in-stent restenosis.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38752901/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240517141110&v=2.18.0.post9+e462414">38752901</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.04.012>10.1016/j.jacc.2024.04.012</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38752901</guid>
<pubDate>Thu, 16 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Irene Santos-Pardo</dc:creator>
<dc:creator>Mikael Andersson Franko</dc:creator>
<dc:creator>Bo Lagerqvist</dc:creator>
<dc:creator>Viveca Ritsinger</dc:creator>
<dc:creator>Björn Eliasson</dc:creator>
<dc:creator>Nils Witt</dc:creator>
<dc:creator>Anna Norhammar</dc:creator>
<dc:creator>Thomas Nyström</dc:creator>
<dc:date>2024-05-16</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Glycemic Control and Coronary Stent Failure in Patients With Type 2 Diabetes Mellitus</dc:title>
<dc:identifier>pmid:38752901</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.04.012</dc:identifier>
</item>
<item>
<title>2024 Lower Extremity Peripheral Artery Disease Guideline-at-a-Glance</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38752900/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240517141110&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 May 8:S0735-1097(24)06826-8. doi: 10.1016/j.jacc.2024.04.003. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38752900/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240517141110&v=2.18.0.post9+e462414">38752900</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.04.003>10.1016/j.jacc.2024.04.003</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38752900</guid>
<pubDate>Thu, 16 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Katie J Bates</dc:creator>
<dc:creator>Mykela M Moore</dc:creator>
<dc:creator>Morgane Cibotti-Sun</dc:creator>
<dc:date>2024-05-16</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>2024 Lower Extremity Peripheral Artery Disease Guideline-at-a-Glance</dc:title>
<dc:identifier>pmid:38752900</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.04.003</dc:identifier>
</item>
<item>
<title>2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38752899/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240517141110&amp;v=2.18.0.post9+e462414
      <description>AIM: The "2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease" provides recommendations to guide clinicians in the treatment of patients with lower extremity peripheral artery disease across its multiple clinical presentation subsets (ie, asymptomatic, chronic symptomatic, chronic limb-threatening ischemia, and acute limb ischemia).</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 May 11:S0735-1097(24)00381-4. doi: 10.1016/j.jacc.2024.02.013. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">AIM: The "2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease" provides recommendations to guide clinicians in the treatment of patients with lower extremity peripheral artery disease across its multiple clinical presentation subsets (ie, asymptomatic, chronic symptomatic, chronic limb-threatening ischemia, and acute limb ischemia).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A comprehensive literature search was conducted from October 2020 to June 2022, encompassing studies, reviews, and other evidence conducted on human subjects that was published in English from PubMed, EMBASE, the Cochrane Library, CINHL Complete, and other selected databases relevant to this guideline. Additional relevant studies, published through May 2023 during the peer review process, were also considered by the writing committee and added to the evidence tables where appropriate.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">STRUCTURE: Recommendations from the "2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease" have been updated with new evidence to guide clinicians. In addition, new recommendations addressing comprehensive care for patients with peripheral artery disease have been developed.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38752899/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240517141110&v=2.18.0.post9+e462414">38752899</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.02.013>10.1016/j.jacc.2024.02.013</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38752899</guid>
<pubDate>Thu, 16 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Writing Committee Members</dc:creator>
<dc:creator>Heather L Gornik</dc:creator>
<dc:creator>Herbert D Aronow</dc:creator>
<dc:creator>Philip P Goodney</dc:creator>
<dc:creator>Shipra Arya</dc:creator>
<dc:creator>Luke Packard Brewster</dc:creator>
<dc:creator>Lori Byrd</dc:creator>
<dc:creator>Venita Chandra</dc:creator>
<dc:creator>Douglas E Drachman</dc:creator>
<dc:creator>Jennifer M Eaves</dc:creator>
<dc:creator>Jonathan K Ehrman</dc:creator>
<dc:creator>John N Evans</dc:creator>
<dc:creator>Thomas S D Getchius</dc:creator>
<dc:creator>J Antonio Gutiérrez</dc:creator>
<dc:creator>Beau M Hawkins</dc:creator>
<dc:creator>Connie N Hess</dc:creator>
<dc:creator>Karen J Ho</dc:creator>
<dc:creator>W Schuyler Jones</dc:creator>
<dc:creator>Esther S H Kim</dc:creator>
<dc:creator>Scott Kinlay</dc:creator>
<dc:creator>Lee Kirksey</dc:creator>
<dc:creator>Debra Kohlman-Trigoboff</dc:creator>
<dc:creator>Chandler A Long</dc:creator>
<dc:creator>Amy West Pollak</dc:creator>
<dc:creator>Saher S Sabri</dc:creator>
<dc:creator>Lawrence B Sadwin</dc:creator>
<dc:creator>Eric A Secemsky</dc:creator>
<dc:creator>Maya Serhal</dc:creator>
<dc:creator>Mehdi H Shishehbor</dc:creator>
<dc:creator>Diane Treat-Jacobson</dc:creator>
<dc:creator>Luke R Wilkins</dc:creator>
<dc:date>2024-05-16</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines</dc:title>
<dc:identifier>pmid:38752899</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.02.013</dc:identifier>
</item>
<item>
<title>Immediate Microvascular Physiology After Mechanical Coronary Reperfusion of STEMI</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38752898/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240517141110&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Apr 22:S0735-1097(24)06758-5. doi: 10.1016/j.jacc.2024.02.051. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38752898/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240517141110&v=2.18.0.post9+e462414">38752898</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.02.051>10.1016/j.jacc.2024.02.051</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38752898</guid>
<pubDate>Thu, 16 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Michel Zeitouni</dc:creator>
<dc:creator>Ghilas Rahoual</dc:creator>
<dc:creator>Gilles Montalescot</dc:creator>
<dc:creator>ACTION study group</dc:creator>
<dc:date>2024-05-16</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Immediate Microvascular Physiology After Mechanical Coronary Reperfusion of STEMI</dc:title>
<dc:identifier>pmid:38752898</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.02.051</dc:identifier>
</item>
<item>
<title>Prognostic Value of Microvascular Resistance Reserve After Percutaneous Coronary Intervention in Patients With Myocardial Infarction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38752897/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240517141110&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: MRR measured directly after primary percutaneous coronary intervention was an independent predictor of the composite of all-cause mortality or hospitalization for heart failure during long-term follow-up.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 May 3:S0735-1097(24)06759-7. doi: 10.1016/j.jacc.2024.02.052. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The microvascular resistance reserve (MRR) has recently been introduced as a novel index to assess the vasodilatory capacity of the microcirculation, independent of epicardial disease. The prognostic value of MRR in ST-segment elevation myocardial infarction (STEMI) is unknown.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The aim of this analysis was to investigate the prognostic value of MRR in patients with STEMI and to compare MRR with cardiovascular magnetic resonance imaging parameters.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: From a pooled analysis of individual patient data from 6 cohorts that measured the index of microcirculatory resistance (IMR) directly after primary percutaneous coronary intervention in patients with STEMI (n = 1,265), a subgroup analysis was performed in patients in whom both MRR and IMR were available. The primary endpoint was the composite of all-cause mortality or hospitalization for heart failure.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Both MRR and IMR could be calculated in 446 patients. The optimal cutoff of MRR to predict the primary endpoint in this STEMI population was 1.25. During a median follow-up of 3.1 years (Q1-Q3: 1.5-6.1 years), the composite of all-cause mortality or hospitalization for heart failure occurred in 27.3% and 5.9% of patients (HR: 4.16; 95% CI: 2.31-7.50; P &lt; 0.001) in the low MRR (≤1.25) and high MRR (>;1.25) groups, respectively. Both IMR and MRR were independent predictors of the composite of all-cause mortality or hospitalization for heart failure.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: MRR measured directly after primary percutaneous coronary intervention was an independent predictor of the composite of all-cause mortality or hospitalization for heart failure during long-term follow-up.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38752897/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240517141110&v=2.18.0.post9+e462414">38752897</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.02.052>10.1016/j.jacc.2024.02.052</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38752897</guid>
<pubDate>Thu, 16 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Rob Eerdekens</dc:creator>
<dc:creator>Mohamed El Farissi</dc:creator>
<dc:creator>Giovanni Luigi De Maria</dc:creator>
<dc:creator>Niels van Royen</dc:creator>
<dc:creator>Marcel van 't Veer</dc:creator>
<dc:creator>Maarten A H van Leeuwen</dc:creator>
<dc:creator>Stephen P Hoole</dc:creator>
<dc:creator>Federico Marin</dc:creator>
<dc:creator>David Carrick</dc:creator>
<dc:creator>Pim A L Tonino</dc:creator>
<dc:creator>Nico H J Pijls</dc:creator>
<dc:creator>Massimo Fineschi</dc:creator>
<dc:creator>Keith G Oldroyd</dc:creator>
<dc:creator>Colin Berry</dc:creator>
<dc:creator>Adrian P Banning</dc:creator>
<dc:creator>William F Fearon</dc:creator>
<dc:creator>Frederik M Zimmermann</dc:creator>
<dc:date>2024-05-16</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Prognostic Value of Microvascular Resistance Reserve After Percutaneous Coronary Intervention in Patients With Myocardial Infarction</dc:title>
<dc:identifier>pmid:38752897</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.02.052</dc:identifier>
</item>
<item>
<title>Genome-Wide CRISPR Screen Identifies an NF2-Adherens Junction Mechanistic Dependency for Cardiac Lineage</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38752370/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240517141110&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: These results provide mechanistic insight into the essential role of NF2 during early epithelial-mesenchymal transition by sequestering the repressive effect of YAP and relieving regulatory roadblocks en route to cardiomyocytes.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 May 16. doi: 10.1161/CIRCULATIONAHA.122.061335. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Cardiomyocyte differentiation involves a stepwise clearance of repressors and fate-restricting regulators through the modulation of BMP (bone morphogenic protein)/Wnt-signaling pathways. However, the mechanisms and how regulatory roadblocks are removed with specific developmental signaling pathways remain unclear.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We conducted a genome-wide CRISPR screen to uncover essential regulators of cardiomyocyte specification in human embryonic stem cells using a myosin heavy chain 6 (<i>MYH6</i>)-GFP (green fluorescence protein) reporter system. After an independent secondary sgRNA validation of 25 candidates, we identified NF2 (neurofibromin 2), a moesin-ezrin-radixin like (MERLIN) tumor suppressor, as an upstream driver of early cardiomyocyte lineage specification. Independent monoclonal <i>NF2</i> knockouts were generated using CRISPR-Cas9, and cell states were inferred through bulk RNA sequencing and protein expression analysis across differentiation time points. Terminal lineage differentiation was assessed by using an in vitro 2-dimensional-micropatterned gastruloid model, trilineage differentiation, and cardiomyocyte differentiation. Protein interaction and post-translation modification of NF2 with its interacting partners were assessed using site-directed mutagenesis, coimmunoprecipitation, and proximity ligation assays.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Transcriptional regulation and trajectory inference from <i>NF2</i>-null cells reveal the loss of cardiomyocyte identity and the acquisition of nonmesodermal identity. Sustained elevation of early mesoderm lineage repressor <i>SOX2</i> and upregulation of late anticardiac regulators <i>CDX2</i> and <i>MSX1</i> in <i>NF2</i> knockout cells reflect a necessary role for <i>NF2</i> in removing regulatory roadblocks. Furthermore, we found that NF2 and AMOT (angiomotin) cooperatively bind to YAP (yes-associated protein) during mesendoderm formation, thereby preventing YAP activation, independent of canonical MST (mammalian sterile 20-like serine-threonine protein kinase)-LATS (large tumor suppressor serine-threonine protein kinase) signaling. Mechanistically, cardiomyocyte lineage identity was rescued by wild-type and NF2 serine-518 phosphomutants, but not NF2 FERM (ezrin-radixin-meosin homology protein) domain blue-box mutants, demonstrating that the critical FERM domain-dependent formation of the AMOT-NF2-YAP scaffold complex at the adherens junction is required for early cardiomyocyte lineage differentiation.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: These results provide mechanistic insight into the essential role of NF2 during early epithelial-mesenchymal transition by sequestering the repressive effect of YAP and relieving regulatory roadblocks en route to cardiomyocytes.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38752370/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240517141110&v=2.18.0.post9+e462414">38752370</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.122.061335>10.1161/CIRCULATIONAHA.122.061335</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38752370</guid>
<pubDate>Thu, 16 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Chang Jie Mick Lee</dc:creator>
<dc:creator>Matias I Autio</dc:creator>
<dc:creator>Wen Hao Zheng</dc:creator>
<dc:creator>Yoohyun Song</dc:creator>
<dc:creator>Shyi Chyi Wang</dc:creator>
<dc:creator>Darren Chen Pei Wong</dc:creator>
<dc:creator>Jingwei Xiao</dc:creator>
<dc:creator>Yike Zhu</dc:creator>
<dc:creator>Permeen Yusoff</dc:creator>
<dc:creator>Xi Yei</dc:creator>
<dc:creator>Wan Kee Chock</dc:creator>
<dc:creator>Boon Chuan Low</dc:creator>
<dc:creator>Marius Sudol</dc:creator>
<dc:creator>Roger S-Y Foo</dc:creator>
<dc:date>2024-05-16</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Genome-Wide CRISPR Screen Identifies an NF2-Adherens Junction Mechanistic Dependency for Cardiac Lineage</dc:title>
<dc:identifier>pmid:38752370</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.122.061335</dc:identifier>
</item>
<item>
<title>Randomized, Multicenter Study to Assess the Effects of Different Doses of Sildenafil on Mortality in Adults With Pulmonary Arterial Hypertension</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38752352/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240517141110&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Sildenafil at 80 mg was noninferior to sildenafil at 5 mg when examining all-cause mortality in adults with PAH. Secondary efficacy end points favored 80 mg of sildenafil over 5 mg. On the basis of these findings, the Food and Drug Administration recently revoked the approval of 5 mg of sildenafil for adults with PAH, reinforced 20 mg TID as the recommended dose, and now allows dose titration up to 80 mg TID, if needed.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 May 16. doi: 10.1161/CIRCULATIONAHA.123.068107. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Sildenafil, approved for pulmonary arterial hypertension (PAH), has a recommended adult dose of 20 mg TID, with a previously approved 5-mg TID dose by the US Food and Drug Administration. Safety concerns arose because of common off-label use of higher doses, particularly after pediatric data linked higher doses to increased mortality. To assess this, the Food and Drug Administration mandated a study evaluating the effects of various sildenafil doses on mortality in adults with PAH.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This randomized, double-blind study compared sildenafil at doses of 5, 20, or 80 mg TID in adults with PAH. The primary objective was noninferiority of 80 mg of sildenafil versus 5 mg for all-cause mortality. Secondary end points included time to clinical worsening and change in 6-minute walk distance at 6 months. Interim analyses were planned at 50% and 75% of the anticipated mortality events. Safety and tolerability were assessed in the intention-to-treat population.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The study was halted after the first interim analysis, demonstrating noninferiority for 80 mg of sildenafil versus 5 mg. Of 385 patients enrolled across all dose groups, 78 died. The primary analysis showed a hazard ratio of 0.51 (99.7% CI, 0.22-1.21; <i>P</i>&lt;0.001 for noninferiority) for overall survival comparing 80 mg of sildenafil with 5 mg. Time to clinical worsening favored 80 mg of sildenafil compared with 5 mg (hazard ratio, 0.44 [99.7% CI, 0.22-0.89]; <i>P</i>&lt;0.001). Sildenafil at 80 mg improved 6-minute walk distance from baseline at 6 months compared with 5 mg (least square mean change, 18.9 m [95% CI, 2.99-34.86]; <i>P</i>=0.0201). No significant differences were found between 80 mg of sildenafil and 20 mg in mortality, clinical worsening, and 6-minute walk distance. Adverse event-related drug discontinuations were numerically higher with 80 mg of sildenafil.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Sildenafil at 80 mg was noninferior to sildenafil at 5 mg when examining all-cause mortality in adults with PAH. Secondary efficacy end points favored 80 mg of sildenafil over 5 mg. On the basis of these findings, the Food and Drug Administration recently revoked the approval of 5 mg of sildenafil for adults with PAH, reinforced 20 mg TID as the recommended dose, and now allows dose titration up to 80 mg TID, if needed.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02060487.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38752352/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240517141110&v=2.18.0.post9+e462414">38752352</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.068107>10.1161/CIRCULATIONAHA.123.068107</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38752352</guid>
<pubDate>Thu, 16 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Marius M Hoeper</dc:creator>
<dc:creator>Ralf Ewert</dc:creator>
<dc:creator>Pavel Jansa</dc:creator>
<dc:creator>Yuriy Sirenko</dc:creator>
<dc:creator>Andris Skride</dc:creator>
<dc:creator>Cecile Balagtas</dc:creator>
<dc:creator>Sarah Hackley</dc:creator>
<dc:creator>Susanne Vogt</dc:creator>
<dc:creator>Paula Abreu</dc:creator>
<dc:creator>Scott Haughie</dc:creator>
<dc:creator>Tarek Hassan</dc:creator>
<dc:creator>Ronald J Oudiz</dc:creator>
<dc:date>2024-05-16</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Randomized, Multicenter Study to Assess the Effects of Different Doses of Sildenafil on Mortality in Adults With Pulmonary Arterial Hypertension</dc:title>
<dc:identifier>pmid:38752352</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.068107</dc:identifier>
</item>
<item>
<title>Allele-Specific Suppression of Variant MHC With High-Precision RNA Nuclease CRISPR-Cas13d Prevents Hypertrophic Cardiomyopathy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38752340/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240517141110&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Our study unveils the great potential of CRISPR-Cas nucleases with high precision in treating inheritable cardiomyopathy and opens a new avenue for therapeutic management of inherited cardiac diseases.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 May 16. doi: 10.1161/CIRCULATIONAHA.123.067890. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Familial hypertrophic cardiomyopathy has severe clinical complications of heart failure, arrhythmia, and sudden cardiac death. Heterozygous single nucleotide variants (SNVs) of sarcomere genes such as <i>MYH7</i> are the leading cause of this type of disease. CRISPR-Cas13 (clustered regularly interspaced short palindromic repeats and their associated protein 13) is an emerging gene therapy approach for treating genetic disorders, but its therapeutic potential in genetic cardiomyopathy remains unexplored.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We developed a sensitive allelic point mutation reporter system to screen the mutagenic variants of Cas13d. On the basis of Cas13d homology structure, we rationally designed a series of Cas13d variants and obtained a high-precision Cas13d variant (hpCas13d) that specifically cleaves the <i>MYH7</i> variant RNAs containing 1 allelic SNV. We validated the high precision and low collateral cleavage activity of hpCas13d through various in vitro assays. We generated 2 HCM mouse models bearing distinct <i>MYH7</i> SNVs and used adenovirus-associated virus serotype 9 to deliver hpCas13d specifically to the cardiomyocytes. We performed a large-scale library screening to assess the potency of hpCas13d in resolving 45 human <i>MYH7</i> allelic pathogenic SNVs.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Wild-type Cas13d cannot distinguish and specifically cleave the heterozygous <i>MYH7</i> allele with SNV. hpCas13d, with 3 amino acid substitutions, had minimized collateral RNase activity and was able to resolve various human <i>MYH7</i> pathological sequence variations that cause hypertrophic cardiomyopathy. In vivo application of hpCas13d to 2 hypertrophic cardiomyopathy models caused by distinct human <i>MYH7</i> analogous sequence variations specifically suppressed the altered allele and prevented cardiac hypertrophy.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Our study unveils the great potential of CRISPR-Cas nucleases with high precision in treating inheritable cardiomyopathy and opens a new avenue for therapeutic management of inherited cardiac diseases.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38752340/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240517141110&v=2.18.0.post9+e462414">38752340</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067890>10.1161/CIRCULATIONAHA.123.067890</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38752340</guid>
<pubDate>Thu, 16 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Ping Yang</dc:creator>
<dc:creator>Yingmei Lou</dc:creator>
<dc:creator>Zilong Geng</dc:creator>
<dc:creator>Zhizhao Guo</dc:creator>
<dc:creator>Shuo Wu</dc:creator>
<dc:creator>Yige Li</dc:creator>
<dc:creator>Kaiyuan Song</dc:creator>
<dc:creator>Ting Shi</dc:creator>
<dc:creator>Shasha Zhang</dc:creator>
<dc:creator>Junhao Xiong</dc:creator>
<dc:creator>Alex F Chen</dc:creator>
<dc:creator>Dali Li</dc:creator>
<dc:creator>William T Pu</dc:creator>
<dc:creator>Lintai Da</dc:creator>
<dc:creator>Yan Zhang</dc:creator>
<dc:creator>Kun Sun</dc:creator>
<dc:creator>Bing Zhang</dc:creator>
<dc:date>2024-05-16</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Allele-Specific Suppression of Variant MHC With High-Precision RNA Nuclease CRISPR-Cas13d Prevents Hypertrophic Cardiomyopathy</dc:title>
<dc:identifier>pmid:38752340</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.067890</dc:identifier>
</item>
<item>
<title>Long QT syndrome: importance of reassessing arrhythmic risk after treatment initiation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38751064/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240517141110&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Beta-blockers often shorten QTc, thus changing risk scores and ICD indications for primary prevention. Yearly risk reassessment with therapy optimization leads to fewer ICD implants (3%) without increasing life-threatening events.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 May 16:ehae289. doi: 10.1093/eurheartj/ehae289. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Risk scores are proposed for genetic arrhythmias. Having proposed in 2010 one such score (M-FACT) for the long QT syndrome (LQTS), this study aims to test whether adherence to its suggestions would be appropriate.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: LQT1/2/3 and genotype-negative patients without aborted cardiac arrest (ACA) before diagnosis or cardiac events (CEs) below age 1 were included in the study, focusing on an M-FACT score ≥2 (intermediate/high risk), either at presentation (static) or during follow-up (dynamic), previously associated with 40% risk of implantable cardioverter defibrillator (ICD) shocks within 4 years.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Overall, 946 patients (26 ± 19 years at diagnosis, 51% female) were included. Beta-blocker (βB) therapy in 94% of them reduced the rate of those with a QTc ≥500 ms from 18% to 12% (P &lt; .001). During 7 ± 6 years of follow-up, none died; 4% had CEs, including 0.4% with ACA. A static M-FACT ≥2 was present in 110 patients, of whom 106 received βBs. In 49/106 patients with persistent dynamic M-FACT ≥2, further therapeutic optimization (left cardiac sympathetic denervation in 55%, mexiletine in 31%, and ICD at 27%) resulted in just 7 (14%) patients with CEs (no ACA), with no CEs in the remaining 57. Additionally, 32 patients developed a dynamic M-FACT ≥2 but, after therapeutic optimization, only 3 (9%) had CEs. According to an M-FACT score ≥2, a total of 142 patients should have received an ICD, but only 22/142 (15%) were implanted, with shocks reported in 3.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Beta-blockers often shorten QTc, thus changing risk scores and ICD indications for primary prevention. Yearly risk reassessment with therapy optimization leads to fewer ICD implants (3%) without increasing life-threatening events.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38751064/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240517141110&v=2.18.0.post9+e462414">38751064</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae289>10.1093/eurheartj/ehae289</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38751064</guid>
<pubDate>Thu, 16 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Veronica Dusi</dc:creator>
<dc:creator>Federica Dagradi</dc:creator>
<dc:creator>Carla Spazzolini</dc:creator>
<dc:creator>Lia Crotti</dc:creator>
<dc:creator>Paolo Cerea</dc:creator>
<dc:creator>Fulvio L F Giovenzana</dc:creator>
<dc:creator>Giulia Musu</dc:creator>
<dc:creator>Matteo Pedrazzini</dc:creator>
<dc:creator>Margherita Torchio</dc:creator>
<dc:creator>Peter J Schwartz</dc:creator>
<dc:date>2024-05-16</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Long QT syndrome: importance of reassessing arrhythmic risk after treatment initiation</dc:title>
<dc:identifier>pmid:38751064</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae289</dc:identifier>
</item>
<item>
<title>Degenerative mitral regurgitation due to flail leaflet: sex-related differences in presentation, management, and outcomes</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38751052/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240517141110&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Females with severe DMR were referred to tertiary centers at a more advanced stage, incurred higher mortality and morbidity under conservative management, and were offered surgery less and later after referral. Ultimately, these sex-related differences yielded persistent excess mortality despite surgery in females with DMR, while males enjoyed restoration of life expectancy, warranting imperative re-evaluation of sex-specific DMR management.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 May 16:ehae265. doi: 10.1093/eurheartj/ehae265. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Presentation, outcome, and management of females with degenerative mitral regurgitation (DMR) are undefined. We analysed sex-specific baseline clinical and echocardiographic characteristics at referral for DMR due to flail leaflets and subsequent management and outcomes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: In the Mitral Regurgitation International Database (MIDA) international registry, females were compared with males regarding presentation at referral, management, and outcome (survival/heart failure), under medical treatment, post-operatively, and encompassing all follow-up.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: At referral, females (n = 650) vs. males (n = 1660) were older with more severe symptoms and higher MIDA score. Smaller cavity diameters belied higher cardiac dimension indexed to body surface area. Under conservative management, excess mortality vs. expected was observed in males [standardized mortality ratio (SMR) 1.45 (1.27-1.65), P &lt; .001] but was higher in females [SMR 2.00 (1.67-2.38), P &lt; .001]. Female sex was independently associated with mortality [adjusted hazard ratio (HR) 1.29 (1.04-1.61), P = .02], cardiovascular mortality [adjusted HR 1.58 (1.14-2.18), P = .007], and heart failure [adjusted HR 1.36 (1.02-1.81), P = .04] under medical management. Females vs. males were less offered surgical correction (72% vs. 80%, P &lt; .001); however, surgical outcome, adjusted for more severe presentation in females, was similar (P ≥ .09). Ultimately, overall outcome throughout follow-up was worse in females who displayed persistent excess mortality vs. expected [SMR 1.31 (1.16-1.47), P &lt; .001], whereas males enjoyed normal life expectancy restoration [SMR 0.92 (0.85-0.99), P = .036].</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Females with severe DMR were referred to tertiary centers at a more advanced stage, incurred higher mortality and morbidity under conservative management, and were offered surgery less and later after referral. Ultimately, these sex-related differences yielded persistent excess mortality despite surgery in females with DMR, while males enjoyed restoration of life expectancy, warranting imperative re-evaluation of sex-specific DMR management.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38751052/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240517141110&v=2.18.0.post9+e462414">38751052</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae265>10.1093/eurheartj/ehae265</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38751052</guid>
<pubDate>Thu, 16 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Jean-Fançois Avierinos</dc:creator>
<dc:creator>Christophe Tribouilloy</dc:creator>
<dc:creator>Francesca Bursi</dc:creator>
<dc:creator>Francesco Grigioni</dc:creator>
<dc:creator>Jean-Louis Vanoverschelde</dc:creator>
<dc:creator>Noémie Resseguier</dc:creator>
<dc:creator>Alexis Théron</dc:creator>
<dc:creator>Agnes Pasquet</dc:creator>
<dc:creator>Julie Pradier</dc:creator>
<dc:creator>Elena Biagini</dc:creator>
<dc:creator>Andrea Barbieri</dc:creator>
<dc:creator>Hector Michelena</dc:creator>
<dc:creator>Giovanni Benfari</dc:creator>
<dc:creator>Dan Rusinaru</dc:creator>
<dc:creator>Stéphane Zaffran</dc:creator>
<dc:creator>David Vancraeynest</dc:creator>
<dc:creator>Fréderic Collart</dc:creator>
<dc:creator>Yohann Bohbot</dc:creator>
<dc:creator>Benjamin Essayagh</dc:creator>
<dc:creator>Maurice Enriquez-Sarano</dc:creator>
<dc:date>2024-05-16</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Degenerative mitral regurgitation due to flail leaflet: sex-related differences in presentation, management, and outcomes</dc:title>
<dc:identifier>pmid:38751052</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae265</dc:identifier>
</item>
<item>
<title>STEP-HFpEF: A Large Step for HFpEF</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38750978/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240517141110&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 May 2:S0735-1097(24)07127-4. doi: 10.1016/j.jacc.2024.04.039. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38750978/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240517141110&v=2.18.0.post9+e462414">38750978</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.04.039>10.1016/j.jacc.2024.04.039</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38750978</guid>
<pubDate>Thu, 16 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Roland R J van Kimmenade</dc:creator>
<dc:creator>Carlijne Hassing</dc:creator>
<dc:date>2024-05-16</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>STEP-HFpEF: A Large Step for HFpEF</dc:title>
<dc:identifier>pmid:38750978</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.04.039</dc:identifier>
</item>





























</channel>
</rss>